The specimen validity testing market size in Europe is expected to be valued at USD 2.13 billion by 2028 from USD 1.57 billion in 2023, growing at a CAGR of 6.29% from 2023 to 2028.
The growing drug abuse and addiction among the European population are majorly driving the European specimen validity testing market growth. In recent years, there has been a rise in the number of people using drugs in the region due to changing lifestyles. The younger generation is primarily addicted to drugs due to poor performance in school or college, parental rejection, abuse, over-controlling by the parents, and divorce. In addition, the consumption of these drugs is mainly due to mental health disorders. As per a recent survey, most employees are using these drugs due to increasing stress levels, anxiety, and depression due to lack of job security, heavy workload, and less income. Specimen validify testing is done to check the levels of drugs present in such people. In addition, the government uses this specimen test to check whether the person is a criminal.
The growing adoption of technological developments in specimen validity testing to develop more accurate and reliable testing methods propels the European specimen validity testing market growth. Key market players focus on developing point-of-care diagnosis for specimen validity testing, boosting the regional market growth. Furthermore, oral specimen validity testing has increased opportunities due to fewer changes required for altering the sample given for the drug abuse test. Furthermore, the use of different advanced technologies in the testing due to the increasing mal practitioners who consume drugs but want to prove that they are not drug addicts also supports the market's need. Such factors are expected to result in the specimen validity testing market growth during the forecast period. Furthermore, the growing drug testing activities and increasing initiatives from the European governments in favor of specimen validity testing favor the market’s growth rate in Europe.
The presence of alternative testing methods is hampering the regional market growth. Furthermore, the high costs associated with specimen validity testing further limit the adoption and the growth rate of the European market. Furthermore, the stringent regulatory environment for specimen validity testing causing extended time for the approval of the products, lack of skilled professionals in the clinical laboratories, and the need for reimbursement policies are further impeding the growth of the European specimen validity testing market.
This research report on the Europe specimen validity testing market has been segmented and sub-segmented into the following categories.
By Product and Service:
By Type:
By Workplaces:
By Country:
Geographically, the European market held a substantial share of the worldwide market in 2021 and the European market is anticipated to witness a notable CAGR during the forecast period owing to the growing number of awareness programs to reduce drug abuse and an increasing number of initiatives and investments by the European governments in the prevention of drug abuse.
The UK specimen validity testing market captured a substantial share of the European market in 2021 and is expected to grow at a prominent CAGR during the forecast period. Drug usage is an increasing problem among UK employees. According to a recent survey, employees reporting to work after taking drugs and alcohol has increased in the last ten years in the United Kingdom. Some of the drugs are cocaine, heroin, hallucinogens, and inhalants. Drug consumption has multiple effects on the brain and the body. This results in showing the effect on the employees' performance at work. As a result, drug testing has been made familiar in some sectors such as construction, logistics, scaffolding, and railways. As per a recent survey, nearly 1 in 11 adults are taking at least one drug in the past year. Cannabis is one of the most used drugs after cocaine in the United Kingdom.
Germany is another potential market for specimen validity testing in the European region and is projected to hold a considerable share of the European market during the forecast period owing to the growing number of drug screening labs in Germany. Most specimen validity testing uses urine as a sample to determine the human body's drug concentration. Increasing research and development in advanced testing with different types of samples and finding new methods to confirm whether the person is a drug addict support the German market growth.
KEY MARKET PLAYERS:
Thermo Fisher Scientific, Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc., Alere Toxicology and American Screening LLC are some of the notable players in the European specimen validity testing market.
Frequently Asked Questions
The Europe Specimen Validity Testing Market is predicted to grow at a CAGR of 6.29% between 2023 to 2028.
The major players operating in the Europe Specimen Validity Testing Market include LabCorp, Quest Diagnostics, Thermo Fisher Scientific, Alere, American Bio Medica Corporation, Express Diagnostics International, Inc., ACM Global Laboratories, and Clinical Reference Laboratory.
The major challenges faced by the Europe Specimen Validity Testing Market include the lack of standardization of testing methods, the high cost of testing equipment, the need for specialized expertise, and the increasing availability of synthetic urine products.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 1400
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region